KR920019371A - 안정화된 인자 ⅷ 제제 - Google Patents

안정화된 인자 ⅷ 제제 Download PDF

Info

Publication number
KR920019371A
KR920019371A KR1019920005733A KR920005733A KR920019371A KR 920019371 A KR920019371 A KR 920019371A KR 1019920005733 A KR1019920005733 A KR 1019920005733A KR 920005733 A KR920005733 A KR 920005733A KR 920019371 A KR920019371 A KR 920019371A
Authority
KR
South Korea
Prior art keywords
solution
activity
amino acid
factor vii
derivatives
Prior art date
Application number
KR1019920005733A
Other languages
English (en)
Other versions
KR100231398B1 (ko
Inventor
프뢰덴베르크 빌프리드
Original Assignee
스타인, 부크
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6429102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR920019371(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 스타인, 부크, 베링베르케 아크티엔게젤샤프트 filed Critical 스타인, 부크
Publication of KR920019371A publication Critical patent/KR920019371A/ko
Application granted granted Critical
Publication of KR100231398B1 publication Critical patent/KR100231398B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

안정화된 인자 Ⅷ 제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 아미노산 또는 이의 염 또는 유도체중의 하나 및 필요에 따라, 청정제 및 유기 중합체를 함유하는 인자 Ⅷ : C 활성을 갖는 용액.
  2. 제1항에 있어서, 아미노산이 천연 아미노산인 용액.
  3. 제1항에 있어서, 아미노산이 염기성 아미노산인 용액.
  4. 제1항에 있어서, 아르기닌과 글라이신을 함유하는 용액.
  5. 제1항에 있어서, 아미노산의 농도가 0.001 내지 1㏖/ℓ인 용액.
  6. 제1항에 있어서, 유기 중합체 또는 비이온성 청정제를 함유하는 용액.
  7. 제1항에 있어서, F Ⅷ : C 활성이 혈장중에서 나타나는 형태의 사람인자 Ⅷ 또는 유전공학적으로 조작된 인자 Ⅷ : C 또는 이들의 유도체로부터 유도되는 용액.
  8. 제1항에 있어서, 특이 F Ⅷ : C 활성이 적어도 1000IU/㎎인 용액.
  9. 제1항에 따른 용액을 함유하는 약제.
  10. 제9항에 있어서, 통상적으로 약학적으로 적합한 안정화 및/또는 완충물질을 함유하는 약제.
  11. 제10항에 있어서, 탄수화물을 함유하는 약제.
  12. 아미노산 또는 이의 염 또는 유도체중의 하나 및, 필요할 경우, 유기 중합체 또는 청정제를 인자 Ⅷ : C 활성을 갖는 용액에 가함을 특징으로 하여 제1항에 따른 용액을 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920005733A 1991-04-09 1992-04-07 응고인자 viii 활성을 지닌 안정화된 액제 KR100231398B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4111393A DE4111393A1 (de) 1991-04-09 1991-04-09 Stabilisierte faktor viii-praeparationen
DEP4111393.4 1991-04-09

Publications (2)

Publication Number Publication Date
KR920019371A true KR920019371A (ko) 1992-11-19
KR100231398B1 KR100231398B1 (ko) 1999-11-15

Family

ID=6429102

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920005733A KR100231398B1 (ko) 1991-04-09 1992-04-07 응고인자 viii 활성을 지닌 안정화된 액제

Country Status (12)

Country Link
US (1) US5565427C1 (ko)
EP (1) EP0508194B1 (ko)
JP (2) JP3777467B2 (ko)
KR (1) KR100231398B1 (ko)
AT (1) ATE160942T1 (ko)
AU (1) AU651188B2 (ko)
CA (1) CA2065553C (ko)
DE (2) DE4111393A1 (ko)
DK (1) DK0508194T3 (ko)
ES (1) ES2111579T4 (ko)
GR (1) GR3025873T3 (ko)
IE (1) IE921124A1 (ko)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100303872B1 (ko) * 1992-10-02 2001-11-22 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) † 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
DE60035260T2 (de) 1999-02-22 2007-10-18 The University Of Connecticut, Farmington Neue albuminfreie faktor viii formulierungen
PT1491208E (pt) * 1999-10-04 2010-05-12 Novartis Vaccines & Diagnostic Composições farmacêuticas contendo polipéptido líquidas estabilizadas
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
SI1599222T1 (sl) 2003-01-08 2009-08-31 Novartis Vaccines & Diagnostic Stabilizirani vodni sestavki, ki obsegajo inhibitor poti tkivnega faktorja (TFPI) ali varianto inhibitorja poti tkivnega faktorja
EP1596887B1 (en) * 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
DE10333317A1 (de) † 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
SI1750733T1 (sl) 2004-05-03 2014-03-31 Emory University POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
DK1835938T3 (da) 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
CA2614006C (en) * 2005-07-02 2014-11-04 Arecor Limited Stable aqueous systems comprising proteins
US7683158B2 (en) * 2006-03-31 2010-03-23 Baxter International Inc. Pegylated factor VIII
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
KR101389376B1 (ko) * 2007-02-23 2014-04-29 에스케이케미칼주식회사 제 ８ 인자 및 그의 유도체의 제조 및 정제 방법
CN101678066B (zh) 2007-04-26 2014-09-24 拜尔健康护理有限责任公司 稳定用于冷冻储藏的重组蛋白液体溶液的方法
JP2012500250A (ja) 2008-08-21 2012-01-05 オクタファルマ アクチェン ゲゼルシャフト 組換えにより産生したヒト第ｖｉｉｉ及び第ｉｘ因子
CA2735376C (en) * 2008-09-03 2016-11-29 Octapharma Ag New protecting compositions for recombinantly produced factor viii
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
NO2440239T3 (ko) 2009-06-09 2018-02-10
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
AR083035A1 (es) * 2010-09-17 2013-01-30 Baxter Int ESTABILIZACION DE INMUNOGLOBULINAS MEDIANTE UNA FORMULACION ACUOSA CON HISTIDINA A pH ACIDO DEBIL A NEUTRO, COMPOSICION ACUOSA DE INMUNOGLOBULINA
KR101948337B1 (ko) 2010-11-05 2019-02-14 박스알타 인코퍼레이티드 증가된 특이 활성도를 갖는 항혈우병 인자 ｖｉｉｉ의 신규 변이체
SG194032A1 (en) 2011-04-08 2013-11-29 Bio Rad Laboratories Sso7-polymerase conjugates with decreased non-specific activity
WO2012138416A1 (en) 2011-04-08 2012-10-11 Bio-Rad Laboratories, Inc. Pcr reaction mixtures with decreased non-specific activity
US9394353B2 (en) 2011-10-18 2016-07-19 Csl Limited Method for improving the stability of purified factor VIII after reconstitution
CN102580062B (zh) * 2012-03-09 2017-03-08 中国医学科学院输血研究所 人凝血因子VIII与vWF复合物或人凝血因子VIII制剂的干热处理稳定剂
JP2014138614A (ja) * 2014-04-09 2014-07-31 Sk Chemicals Co Ltd 第ｖｉｉｉ因子とその誘導体の製造及び精製方法
KR102192494B1 (ko) 2014-08-04 2020-12-18 시에스엘 리미티드 인자 viii 제형
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
EP4240757A2 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB941019A (en) * 1961-04-27 1963-11-06 Crookes Lab Ltd Improvements in and relating to the stability of anti-haemophilic globulin (factor viii)
EP0035204B2 (en) * 1980-03-05 1991-05-22 Miles Inc. Pasteurized therapeutically active protein compositions
DE3481109D1 (de) * 1983-05-09 1990-03-01 Novo Nordisk As Antihaemophilie-faktor-viii-konzentrat und dessen herstellungsverfahren.
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
FR2644064B1 (fr) * 1989-02-17 1994-05-27 Aquitaine Dev Transf Sanguine Procede de fabrication du facteur antihemophilique fviiic ayant une tres haute purete et facteur antihemophilique fviiic ainsi obtenu, ainsi que composition pharmaceutique le contenant
US5110907A (en) * 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
DE3926034C3 (de) * 1989-08-07 1996-11-21 Behringwerke Ag Verfahren zur Herstellung eines stabilen Faktors VIII
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
IT1248723B (it) * 1990-06-12 1995-01-26 Scalvo S P A Processo per la purificazione del fattore viii e fattore viii ottenuto con tale processo
JP4021982B2 (ja) * 1998-03-03 2007-12-12 信越化学工業株式会社 ハイブリッド型ウイグラ

Also Published As

Publication number Publication date
GR3025873T3 (en) 1998-04-30
CA2065553C (en) 2003-06-10
US5565427C1 (en) 2002-07-23
DE59209051D1 (de) 1998-01-22
CA2065553A1 (en) 1992-10-10
US5565427A (en) 1996-10-15
AU1470292A (en) 1992-10-15
ES2111579T3 (es) 1998-03-16
ATE160942T1 (de) 1997-12-15
DK0508194T3 (da) 1998-08-24
IE921124A1 (en) 1992-10-21
DE4111393A1 (de) 1992-10-15
EP0508194B1 (de) 1997-12-10
KR100231398B1 (ko) 1999-11-15
JP3809501B2 (ja) 2006-08-16
JP2002097199A (ja) 2002-04-02
ES2111579T4 (es) 2011-12-29
JP3777467B2 (ja) 2006-05-24
EP0508194A1 (de) 1992-10-14
JPH0597702A (ja) 1993-04-20
AU651188B2 (en) 1994-07-14

Similar Documents

Publication Publication Date Title
KR920019371A (ko) 안정화된 인자 ⅷ 제제
ES2526707T3 (es) Purificación y estabilización de péptidos y proteínas en agentes farmacéuticos
ATE298561T1 (de) Orale dareichungsform
NO993709D0 (no) Stabilisert blanding omfattende fibrinogen
KR950703987A (ko) G-csf의 안정한 동결건조된 약제학적 제제(stable lyophilized pharma ceutical preparations g-csf)
KR970706017A (ko) 안정한 알파 인터페론 수용액 제형(Stable, aqueous alfainterfer on solution for mulations)
DE69230610D1 (de) Peptide mit zyklischen Hauptketten, deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
ATE205090T1 (de) Eine glucagon enthaltende pharmazeutische zubereitung
ATE75945T1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
KR940703689A (ko) 성장호르몬과 아스파라진으로 이루어지는 안정화된 약학제제(a stabil-ized pharmaceutical formulation comprising growth gormone and asparagine)
KR910009246A (ko) 폴리펩타이드를 함유하는 피하투여용 또는 근육내 투여용 약제
DE69111205D1 (de) Stabilisierung von Calcitonin enthaltenden pharmazeutischen Verbindungen.
ATE365542T1 (de) Lyophilisierbare pharmazeutische plazebozusammensetzung , insbesondere auf basis von proteinen oder polypeptiden, zur nachahmung eines arzneimittels
KR950024769A (ko) 고농도 tcf 제제
KR910005886A (ko) 안정화 백혈구 인터페론
DK1153615T3 (da) Farmaceutisk formulering til intravenøs eller intramuskulær octreotid-indgivelse
DE69423623D1 (de) Aminosäureergänzung
GT199200002A (es) Derivados de aminoacidos

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110719

Year of fee payment: 13

EXPY Expiration of term